Cargando…
Phellinus gilvus-derived protocatechualdehyde induces G0/G1 phase arrest and apoptosis in murine B16-F10 cells
Protocatechualdehyde (PCA) is considered to be the main phenolic component of Phellinus gilvus responsible for its anticancer properties. Previous studies have demonstrated that PCA can have an anticancer effect on multiple cancer types, but little is known about the effect of PCA on melanoma cells....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002996/ https://www.ncbi.nlm.nih.gov/pubmed/31894337 http://dx.doi.org/10.3892/mmr.2019.10896 |
Sumario: | Protocatechualdehyde (PCA) is considered to be the main phenolic component of Phellinus gilvus responsible for its anticancer properties. Previous studies have demonstrated that PCA can have an anticancer effect on multiple cancer types, but little is known about the effect of PCA on melanoma cells. The present study investigated the inhibitory abilities and potential anticancer mechanisms of PCA on B16-F10 cells using MTT assay. Cell apoptosis and cell cycle were assessed by flow cytometry using Annexin V-FITC and propidium iodide staining. Whole-transcriptome analysis was used to investigate the effects of PCA on gene expression. PCA significantly decreased cell viability, induced cell cycle arrest at G0/G1 phase and promoted apoptosis of B16-F10 cells, suggesting that PCA could have anticancer effects against melanoma cells. Whole-transcriptome analysis indicated that PCA treatment upregulated genes involved in histone modification and decreased the transcription of genes involved in DNA repair and replication. Kyoto Encyclopedia of Genes and Genomes analysis showed that PCA treatment enhanced the complement and coagulation cascades, and the p53 signaling pathway. The present results indicated that PCA could act as an antitumor agent in melanoma cells, which may provide experimental support for the development of novel therapies to treat melanoma. |
---|